Effect of digitalis treatment on survival after acute myocardial infarction

J. Thomas Bigger, Joseph L. Fleiss, Linda M. Rolnitzky, Jacques P. Merab, Kevin J. Ferrick

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

To determine whether treatment with digitalis is associated with decreased survival after acute myocardial infarction (AMI), data from 504 patients who were enrolled in a postinfarction natural history study were analyzed. At the time of discharge, 229 patients (45%) were taking digitalis. After 3 years of follow-up, the cumulative survival rate for patients discharged on a regimen of digitalis was 66%, compared with 87% for those not treated (p < 0.001). Univariate analysis showed that statistically significant differences existed between the 2 groups with respect to age, previous AMI, left ventricular failure in the coronary care unit, atrial fibrillation in the coronary care unit, peak creatine kinase levels, enlarged heart and pulmonary vascular congestion on the discharge chest x-ray, ventricular arrhythmias and treatment with diuretic, antiarrhythmic and β-blocking drugs. Survival analysis using Cox's regression model showed that the association between digitalis and decreased survival was of borderline significance after adjustment for atrial fibrillation and left ventricular failure. Serum digoxin concentration was measured in 83% of the patients who took digitalis. Survival was inversely and significantly related to serum digoxin, i.e., the higher the serum digoxin concentration, the lower the long-term survival rate. After adjusting for atrial fibrillation and left ventricular failure, serum digoxin was not significantly related to survival. Taken together with the results of 3 other large, nonrandomized studies of digitalis treatment after AMI, this study suggests that digitalis treatment may have adverse effects on survival during follow-up. Until this question is definitively answered by controlled, randomized clinical studies, clinicians should ask themselves, in each case, whether treatment is really needed for left ventricular dysfunction after myocardial infarction and, if so, which treatment has the best risk-benefit ratio.

Original languageEnglish (US)
Pages (from-to)623-630
Number of pages8
JournalThe American Journal of Cardiology
Volume55
Issue number6
DOIs
StatePublished - Mar 1 1985
Externally publishedYes

Fingerprint

Digitalis
Myocardial Infarction
Digoxin
Survival
Atrial Fibrillation
Coronary Care Units
Serum
Therapeutics
Survival Rate
Patient Discharge
Anti-Arrhythmia Agents
Cardiomegaly
Left Ventricular Dysfunction
Survival Analysis
Creatine Kinase
Natural History
Proportional Hazards Models
Diuretics
Blood Vessels
Cardiac Arrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of digitalis treatment on survival after acute myocardial infarction. / Bigger, J. Thomas; Fleiss, Joseph L.; Rolnitzky, Linda M.; Merab, Jacques P.; Ferrick, Kevin J.

In: The American Journal of Cardiology, Vol. 55, No. 6, 01.03.1985, p. 623-630.

Research output: Contribution to journalArticle

Bigger, J. Thomas ; Fleiss, Joseph L. ; Rolnitzky, Linda M. ; Merab, Jacques P. ; Ferrick, Kevin J. / Effect of digitalis treatment on survival after acute myocardial infarction. In: The American Journal of Cardiology. 1985 ; Vol. 55, No. 6. pp. 623-630.
@article{7daf6c5c00e8428891b3cd7dbf7c40ad,
title = "Effect of digitalis treatment on survival after acute myocardial infarction",
abstract = "To determine whether treatment with digitalis is associated with decreased survival after acute myocardial infarction (AMI), data from 504 patients who were enrolled in a postinfarction natural history study were analyzed. At the time of discharge, 229 patients (45{\%}) were taking digitalis. After 3 years of follow-up, the cumulative survival rate for patients discharged on a regimen of digitalis was 66{\%}, compared with 87{\%} for those not treated (p < 0.001). Univariate analysis showed that statistically significant differences existed between the 2 groups with respect to age, previous AMI, left ventricular failure in the coronary care unit, atrial fibrillation in the coronary care unit, peak creatine kinase levels, enlarged heart and pulmonary vascular congestion on the discharge chest x-ray, ventricular arrhythmias and treatment with diuretic, antiarrhythmic and β-blocking drugs. Survival analysis using Cox's regression model showed that the association between digitalis and decreased survival was of borderline significance after adjustment for atrial fibrillation and left ventricular failure. Serum digoxin concentration was measured in 83{\%} of the patients who took digitalis. Survival was inversely and significantly related to serum digoxin, i.e., the higher the serum digoxin concentration, the lower the long-term survival rate. After adjusting for atrial fibrillation and left ventricular failure, serum digoxin was not significantly related to survival. Taken together with the results of 3 other large, nonrandomized studies of digitalis treatment after AMI, this study suggests that digitalis treatment may have adverse effects on survival during follow-up. Until this question is definitively answered by controlled, randomized clinical studies, clinicians should ask themselves, in each case, whether treatment is really needed for left ventricular dysfunction after myocardial infarction and, if so, which treatment has the best risk-benefit ratio.",
author = "Bigger, {J. Thomas} and Fleiss, {Joseph L.} and Rolnitzky, {Linda M.} and Merab, {Jacques P.} and Ferrick, {Kevin J.}",
year = "1985",
month = "3",
day = "1",
doi = "10.1016/0002-9149(85)90125-0",
language = "English (US)",
volume = "55",
pages = "623--630",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of digitalis treatment on survival after acute myocardial infarction

AU - Bigger, J. Thomas

AU - Fleiss, Joseph L.

AU - Rolnitzky, Linda M.

AU - Merab, Jacques P.

AU - Ferrick, Kevin J.

PY - 1985/3/1

Y1 - 1985/3/1

N2 - To determine whether treatment with digitalis is associated with decreased survival after acute myocardial infarction (AMI), data from 504 patients who were enrolled in a postinfarction natural history study were analyzed. At the time of discharge, 229 patients (45%) were taking digitalis. After 3 years of follow-up, the cumulative survival rate for patients discharged on a regimen of digitalis was 66%, compared with 87% for those not treated (p < 0.001). Univariate analysis showed that statistically significant differences existed between the 2 groups with respect to age, previous AMI, left ventricular failure in the coronary care unit, atrial fibrillation in the coronary care unit, peak creatine kinase levels, enlarged heart and pulmonary vascular congestion on the discharge chest x-ray, ventricular arrhythmias and treatment with diuretic, antiarrhythmic and β-blocking drugs. Survival analysis using Cox's regression model showed that the association between digitalis and decreased survival was of borderline significance after adjustment for atrial fibrillation and left ventricular failure. Serum digoxin concentration was measured in 83% of the patients who took digitalis. Survival was inversely and significantly related to serum digoxin, i.e., the higher the serum digoxin concentration, the lower the long-term survival rate. After adjusting for atrial fibrillation and left ventricular failure, serum digoxin was not significantly related to survival. Taken together with the results of 3 other large, nonrandomized studies of digitalis treatment after AMI, this study suggests that digitalis treatment may have adverse effects on survival during follow-up. Until this question is definitively answered by controlled, randomized clinical studies, clinicians should ask themselves, in each case, whether treatment is really needed for left ventricular dysfunction after myocardial infarction and, if so, which treatment has the best risk-benefit ratio.

AB - To determine whether treatment with digitalis is associated with decreased survival after acute myocardial infarction (AMI), data from 504 patients who were enrolled in a postinfarction natural history study were analyzed. At the time of discharge, 229 patients (45%) were taking digitalis. After 3 years of follow-up, the cumulative survival rate for patients discharged on a regimen of digitalis was 66%, compared with 87% for those not treated (p < 0.001). Univariate analysis showed that statistically significant differences existed between the 2 groups with respect to age, previous AMI, left ventricular failure in the coronary care unit, atrial fibrillation in the coronary care unit, peak creatine kinase levels, enlarged heart and pulmonary vascular congestion on the discharge chest x-ray, ventricular arrhythmias and treatment with diuretic, antiarrhythmic and β-blocking drugs. Survival analysis using Cox's regression model showed that the association between digitalis and decreased survival was of borderline significance after adjustment for atrial fibrillation and left ventricular failure. Serum digoxin concentration was measured in 83% of the patients who took digitalis. Survival was inversely and significantly related to serum digoxin, i.e., the higher the serum digoxin concentration, the lower the long-term survival rate. After adjusting for atrial fibrillation and left ventricular failure, serum digoxin was not significantly related to survival. Taken together with the results of 3 other large, nonrandomized studies of digitalis treatment after AMI, this study suggests that digitalis treatment may have adverse effects on survival during follow-up. Until this question is definitively answered by controlled, randomized clinical studies, clinicians should ask themselves, in each case, whether treatment is really needed for left ventricular dysfunction after myocardial infarction and, if so, which treatment has the best risk-benefit ratio.

UR - http://www.scopus.com/inward/record.url?scp=0021948653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021948653&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(85)90125-0

DO - 10.1016/0002-9149(85)90125-0

M3 - Article

VL - 55

SP - 623

EP - 630

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -